Cited by 415Cancer Genomics and DiagnosticsLung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib

Punnoose, Elizabeth A., Atwal, Siminder, Liu, Weiqun, Raja, Rajiv, Fine, Bernard M., Hughes, Brett G.M., Hicks, Rodney J., Hampton, Garret M., Amler, Lukas C., Pirzkall, Andrea, Lackner, Mark R.·2012·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-11-3148

Published version of a preprint

Open this paper in CoChat — free account

Abstract

PURPOSE: Elevated levels or increases in circulating tumor cells (CTC) portend poor prognosis in patients with epithelial cancers. Less is known about CTCs as surrogate endpoints or their use for predictive biomarker evaluation. This study investigated the utility of CTC enumeration and characterization using the CellSearch platform, as well as mutation detection in circulating tumor DNA (ctDNA), in patients with advanced non-small cell lung cancer (NSCLC). EXPERIMENTAL DESIGN: Forty-one patients were enrolled in a single-arm phase II clinical trial of erlotinib and pertuzumab. Peripheral blood was analyzed for CTC enumeration, EGFR expression in CTCs, and detection of oncogenic mutations in CTCs and ctDNA. Changes in CTC levels were correlated with 2[18F]fluoro-2-deoxy-D-glucose-positron emission tomographic (FDG-PET) and computed tomographic (CT) imaging and survival endpoints. RESULTS: CTCs were detected (≥ 1 CTC) at baseline in 78% of patients. Greater sensitivity for mutation detection was observed in ctDNA than in CTCs and detected mutations were strongly concordant with mutation status in matched tumor. Higher baseline CTC counts were associated with response to treatment by Response Evaluation Criteria in Solid Tumors (RECIST, P = 0.009) and decreased CTC counts upon treatment were associated with FDG-PET and RECIST response (P = 0.014 and P = 0.019) and longer progression-free survival (P = 0.050). CONCLUSION: These data provide evidence of a correlation between decreases in CTC counts and radiographic response by either FDG-PET or RECIST in patients with advanced NSCLC. These findings require prospective validation but suggest a potential role for using CTC decreases as an early indication of response to therapy and ctDNA for real-time assessment of mutation status from blood.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-11-3148

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,602
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
Allard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., & Terstappen, L. W. M. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0378 · Cited by 2,542
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Bono, J. S. D., Scher, H. I., Montgomery, B., Parker, C. C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. M. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,189
Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
Cohen, S. J., Punt, C. J. A., Iannotti, N. O., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., Picus, J., Morse, M., Mitchell, E. P., Miller, M. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8923 · Cited by 1,876
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations
Young, H. E., Baum, R. P., Cremerius, U., Herholz, K., Hoekstra, O. S., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,716
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S., Herbst, R. S., Ince, W. L., Janne, P. A., Januario, T., Johnson, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.857 · Cited by 1,453
Self-citation
Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System
Riethdorf, S., Fritsche, H. A., Müller, V., Rau, T., Schindlbeck, C., Rack, B. K., Janni, W., Coith, C., Beck, K., Jänicke, F., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1695 · Cited by 1,365
Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
Cristofanilli, M., Hayes, D. F., Budd, G. T., Ellis, M. J., Stopeck, A., Reuben, J. M., Doyle, G. V., Matera, J., Allard, W. J., Miller, M. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.140 · Cited by 1,134
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., & Sliwkowski, M. X. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00083-2 · Cited by 1,126
Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival
Hayes, D. F., Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Miller, M. C., Matera, J., Allard, W. J., Doyle, G. V., & Terstappen, L. W. M. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2821 · Cited by 1,032
Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer
Krebs, M., Sloane, R. A. S., Priest, L. J. C., Lancashire, L., Hou, J., Greystoke, A., Ward, T. H., Ferraldeschi, R., Hughes, A. M., Clack, G., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.7045 · Cited by 884
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873
Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer
Danila, D. C., Heller, G., Gignac, G. A., Gonzalez-Espinoza, R., Anand, A., Tanaka, E., Lilja, H. G., Schwartz, L. B., Larson, S. M., Fleisher, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1506 · Cited by 665
Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer
Sequist, L. V. D., Bell, D. W., Lynch, T. J., & Haber, D. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3585 · Cited by 625
Characterization of ERG , AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
Attard, G., Swennenhuis, J. F., Olmos, D., Reid, A. H. M., Vickers, E., A'Hern, R., Levink, R., Coumans, F., Moreira, J., Riisnaes, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3667 · Cited by 533
Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial
Riethdorf, S., Müller, V., Zhang, L., Rau, T., Loibl, S., Komor, M., Roller, M., Huober, J., Fehm, T. N., Schrader, I., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2042 · Cited by 489
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial
Fehm, T. N., Müller, V., Aktas, B., Janni, W., Schneeweiß, A., Stickeler, E., Lattrich, C., Löhberg, C. R., Solomayer, E. F., Rack, B. K., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1163-x · Cited by 354
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab
Adams, C. W., Allison, D. E., Flagella, K. M., Presta, L. G., Clarke, J. B., Dybdal, N. O., McKeever, K., & Sliwkowski, M. X. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0058-x · Cited by 316
Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting
Eberhard, D. A., Giaccone, G., & Johnson, B. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9858 · Cited by 302
Molecular Biomarker Analyses Using Circulating Tumor Cells
Punnoose, E. A., Atwal, S. K., Spoerke, J. M., Savage, H. M., Pandita, A., Yeh, R., Pirzkall, A., Fine, B. M., Amler, L. C., Chen, D. S., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012517 · Cited by 298
Self-citation
Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor
Bono, J. S. D., Attard, G., Adjei, A. A., Pollak, M., Fong, P. C. C., Haluska, P., Roberts, L., Melvin, C. L., Repollet, M., Chianese, D. A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0268 · Cited by 192
Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer
Herbst, R. S., Davies, A. M., Natale, R. B., Dang, T. P., Schiller, J. H., Garland, L. L., Miller, V. A., Mendelson, D. S., den Abbeele, A. D. V., Melenevsky, Y. V., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0460 · Cited by 101
Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations
Berghmans, T., Pasleau, F., Paesmans, M., Bonduelle, Y., Cadranel, J. L., Toth, I. C., Garcia, C., Giner, V., Holbrechts, S., Lafitte, J., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00190310 · Cited by 49
The partition method for poset-free families
Griggs, J. R., & Li, W. (2012) · Journal of Combinatorial Optimization · doi:10.1007/s10878-012-9476-9 · Cited by 47
Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer
Johnson, B. E., & Janne, P. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0629 · Cited by 40

Research works printed but not linked: 2

Ries, 2005, Cancer Statistics Review, 1975–2002
Hughes B, 2011, Combination of pertuzumab and erlotinib as 2nd/3rd-line treatment for patients with metastatic non-small cell lung cancer: safety and anti-tumour activity by FDG-PET/CT imaging changes, ECCO/ESMO European Multidisciplinary Congress; 23–27

Sorted by citations

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Liquid biopsy: monitoring cancer-genetics in the blood
Crowley, E. H., Nicolantonio, F. D., Loupakis, F., & Bardelli, A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.110 · Cited by 1,857
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624

See all 415

Authors: Punnoose, E. A., Atwal, S., Liu, W., Raja, R., Fine, B. M., Hughes, B. G. M., Hicks, R. J., Hampton, G. M., Amler, L. C., Pirzkall, A., & Lackner, M. R.
Affiliations: Genentech (US)
ORCID: Punnoose, Elizabeth A.
Liu, Weiqun
Raja, Rajiv
Fine, Bernard M.
Hughes, Brett G.M.
Hicks, Rodney J.
Lackner, Mark R.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2012-04-15
Volume: 18
Issue: 8
Pages: 2391-2401
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-11-3148
OpenAlex: W2103077070
Cited by: 415
References: 29
Citations by year: 2026: 2 · 2025: 6 · 2024: 14 · 2023: 26 · 2022: 17 · 2021: 27 · 2020: 33 · 2019: 39 · 2018: 34 · 2017: 56 · 2016: 53 · 2015: 38 · 2014: 38 · 2013: 23 · 2012: 8
FWCI: 11.36
Type: journal article
Language: en
Open access: closed
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: circulating tumor cells, circulating tumor DNA, non-small cell lung cancer, pertuzumab, erlotinib, EGFR expression, oncogenic mutations, predictive biomarkers, treatment response monitoring, CellSearch, FDG-PET, RECIST, progression-free survival, liquid biopsy
MeSH terms: Erlotinib Hydrochloride, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, DNA, Neoplasm, Female, Genotype, Humans, Lung Neoplasms, Male, Mutation, Neoplastic Cells, Circulating, Quinazolines, Biomarkers, Tumor, Disease-Free Survival, Endpoint Determination, Positron-Emission Tomography, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks